Category: Uncategorized

    Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news that the Company has been granted permission to conduct a Phase 1 clinical study of an intravenous formulation of AP-188 or DMT for the treatment of stroke. The study will be conducted in the Netherlands at the Centre for Human Drug Research in Leiden. The screening for patients is expected to begin in Q4 of this year. The purpose of the study is to identify the safety, tolerability, and pharmacokinetics of DMT when administered as an intravenous bolus followed by prolonged infusion. …

Streetwise Reports – Will Pharma Co. Keep Pushing Higher After Full Data Set Released on Lung Disease Study? One small-cap pharma co. just published more good news on a possible treatment for patients suffering from idiopathic pulmonary fibrosis, a lung disease that’s usually terminal. Find out why the company has more near-term catalysts and may continue to build on an 84% gain since a private placement in mid-August. Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA), a Canadian pharmaceutical development company, reports that the full data set from its Phase 2a study evaluating NP-120 or Ifenprodil to potentially treat idiopathic pulmonary fibrosis …

Expert Chris Temple gives his view on Algernon Pharmaceuticals stock in light of its positive results for its Phase 2a Study for the treatment of idiopathic pulmonary fibrosis and chronic cough. Aside from gold and silver stocks (which, as a group, are selling today at $1,700 gold at levels they were at several years ago with gold nearer $1,200 an ounce!) I don’t think there’s been any sector sold off over the last 12-18 months in a similarly wholesale fashion as much as biotech stocks, especially the more speculative ones. That has opened up a lot of opportunities, including in …

Proactive Investors Interview – Algernon Pharmaceuticals Releases Positive Data from Study on Ifenprodil for IPF and Chronic Cough   Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news that the Company has now reported the full data set of its Phase 2a Study of Ifenprodil for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Cough. Mr. Moreau explains to Proactive that the Company saw positive data from this study which measured efficacy in lung function and patient-reported outcomes of both IPF and Chronic Cough. The data showed statistically significant improvements in measures of cough. As …

Streetwise Reports – Hedge Fund Doubles Position in Biotech Co. A Canadian hedge fund doubled its stake in a tiny biotech that demonstrated promising results in a study that used a former Sanofi drug called Ifenprodil to treat idiopathic pulmonary fibrosis and chronic cough. Find out the name of the company and why one analyst has given it a 12-month CA$25 target price — a 560% increase from the unit price in its recent placement. Buoyed by the strength of a 150,000-share lead order from Toronto-based hedge fund AlphaNorth Asset Management. The deal makes Vancouver-based Algernon a top 20 holding …

  Since covering Algernon 6 months ago, the biotech sector has rebounded significantly and raised the valuations of many research and development companies. The XBI Biotech ETF is up 18% since the beginning of June to late July. Meanwhile, the next best performing sector is healthcare (+1.22%), followed by technology (+.82%), financials (-4.21%), and energy (-10.23%). Algernon caught the wave and their stock has rebounded 26% since mid-July (as of 8/16/22). In addition to the general bullish sentiment in the sector, Algernon has improved its fundamentals to warrant a substantially higher valuation than it’s $4.1M market cap (as of 8/16/22). …

We are maintaining our SPECULATIVE BUY rating & C$25 Target Price. Dr Jacky Smith is a key opinion leader (KOL) in chronic cough. An additional statistical analysis of Algernon’s Phase 2a data in IPF patients with chronic cough confirmed Dr. Smith’s original positive impression of the study. Additional Positive Phase 2a Cough Data – Analyzed by Dr. Jacky Smith Dr. Jacky Smith, Professor of Respiratory Medicine at the University of Manchester, and an Honorary Consultant at Manchester University NHS Foundation Trust reviewed the Algernon Phase 2a data in IPF patients with chronic cough. Dr Jacky Smith is an expert in …

  Most idiopathic pulmonary fibrosis (IPF) patients treated with NP-120 (ifenprodil) in a 12-week clinical trial saw their lung function improve or stabilize, and most also experienced an easing in coughing, according to top-line data announced by the therapy’s developer, Algernon Pharmaceuticals. “Simply put, the IPF data is better than we could have imagined,” Christopher J. Moreau, Algernon’s CEO, said in a company press release. A larger and placebo-controlled trial is being planned.   The proof-of-concert Phase 2 clinical trial (NCT04318704) enrolled 20 people with IPF and chronic cough, all of whom were treated with NP-120 (20 mg, taken three times daily) for 12 …

Patients in Algernon’s Phase 2a Study Show Improved Lung Capacity One junior biotech company that attempts to treat current health problems with older previously approved drugs, recently completed a Phase 2 study that showed promise in the treatment of idiopathic pulmonary fibrosis (IPF) and chronic cough. It moved the small company a step closer to bringing the treatment to market. A 12-week, Stage 2a proof of concept study using NP-120 or Ifenprodil to treat idiopathic pulmonary fibrosis (IPF) and chronic cough was recently completed by Vancouver-based Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) — and it demonstrated that 13 out of …

Research Capital Corporation – Breathing Easier – Liftoff! – IPF Phase 2a Data Hits   ACTION: Maintaining SPECULATIVE BUY Rating and Target Price AGN reported topline results of a Phase 2a trial with ifenprodil in IPF patients with chronic cough – the idiopathic pulmonary fibrosis (IPF) data hit its endpoint -showing promising initial efficacy. We are maintaining a SPECULATIVE BUY rating. Our target price of C$25.00 is based on a probability-adjusted NPV analysis of ifenprodil.   DETAILS: Topline Phase 2a Results with Ifenprodil in IPF Patients with Chronic Cough Design of the Trial: This open-label study enrolled 20 idiopathic pulmonary …